Given that abnormally low SMURF2 expression is responsible for elevated RACK1 levels and ovarian tumor progression, our results suggest that targeting RACK1 in patients with abnormally low SMURF2 expression may be a viable stratified treatment approach. The gene discussed is SMURF2; the disease is ovarian neoplasm.